Zehra Dilek Kanmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zehra Dilek Kanmaz has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Gülfidan Aras
Department of Chest Diseases, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul
3 shared publications - Sedat Altin
Department of Chest Disease, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
2 shared publications - Tugba Mandal Zi̇rEk
UNIVERSITY OF HEALTH SCIENCES, İSTANBUL YEDİKULE HEALTH RESEARCH CENTER FOR PULMONOLOGY AND THORACIC SURGERY, DEPARTMENT OF INTERNAL MEDICINE
2 shared publications - Esin Tuncay
Yedikule Chest Dis & Thorac Surg Training & Res H, Dept Pulmonol, Istanbul, Turkey
1 shared publication - Esin Tuncay1 shared publication
- Fatma Tokgoz Akyil
Department of Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
1 shared publication
Latest Publications
- 21 May 2026
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 4 (2) , 13-19
Intensive care utilization in COPD and advanced-stage lung cancer
Aims: Patients with terminal lung cancer and COPD frequently require intensive care unit (ICU) care, yet survival benefits remain uncertain. We evaluated ICU outcomes and the impact of palliative care integration in a tertiary chest hospital. Methods: A retrospective review included 731 patients transferred to ICUs between 2013–2019. Outcomes were compared before and after the establishment of a palliative care unit in 2016. Results: Lung cancer accounted for 33.5% of cases and COPD for 66.5%. ICU mortality was 91.7% in cancer and 82% in COPD, with only 10.5% overall survival. Post-discharge survival remained poor, as 4.1% died shortly after ICU transfer. Mean ICU stays were 7.8 and 11.6 days, respectively. Palliative care availability did not significantly change ICU referral rates. Conclusion: ICU treatment for end-stage COPD and lung cancer is associated with very limited survival. Effective palliative care integration and structured end-of-life decision-making are urgently needed to optimize ICU use.
- 21 May 2026
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 4 (2) , 13-19
Intensive care utilization in COPD and advanced-stage lung cancer
Aims: Patients with terminal lung cancer and COPD frequently require intensive care unit (ICU) care, yet survival benefits remain uncertain. We evaluated ICU outcomes and the impact of palliative care integration in a tertiary chest hospital. Methods: A retrospective review included 731 patients transferred to ICUs between 2013–2019. Outcomes were compared before and after the establishment of a palliative care unit in 2016. Results: Lung cancer accounted for 33.5% of cases and COPD for 66.5%. ICU mortality was 91.7% in cancer and 82% in COPD, with only 10.5% overall survival. Post-discharge survival remained poor, as 4.1% died shortly after ICU transfer. Mean ICU stays were 7.8 and 11.6 days, respectively. Palliative care availability did not significantly change ICU referral rates. Conclusion: ICU treatment for end-stage COPD and lung cancer is associated with very limited survival. Effective palliative care integration and structured end-of-life decision-making are urgently needed to optimize ICU use.
- Open Access
- 15 August 2024
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 2 (3) , 52-57
Frightening symptom hemoptysis: Analysis of etiology, mortality, and treatment outcomes in a large cohort from the chest disease center in Turkiye
Aims: Hemoptysis can indicate serious, potentially life-threatening conditions. The etiology varies by region and can include tuberculosis (TB) in developing countries and malignancies in developed regions. Methods: This retrospective cohort study reviewed medical records of 400 hospitalized hemoptysis patients between June 2012 and March 2016. Data collected included patient demographics, comorbidities, hemoptysis volume, diagnostic tests, treatments, and outcomes. Survival rates and readmissions were tracked for 2-6 years post-discharge. Results: Of the 400 patients, 88 (22%) were female and 312 (78%) were male. The leading causes of hemoptysis were bronchiectasis (14%), sequela of tuberculosis (TB sequelae; 19%), and malignancy (22.8%). The most common causes in male patients were lung cancer (27.2%) and TB sequelae (21.8%). Bronchiectasis accounted for 28.4% of cases in female patients, followed by drug-induced hemoptysis at 14.8%. The in-hospital mortality rate was 1% (n = 4), with severe hemoptysis present in all four patients who died during admission for hemoptysis. The 2–6-year survival rate was 70.8% for women and 56.1% for men (p = 0.005). The factors found to significantly worsen mortality risk were lung malignancy, age >65, diabetes, and chronic obstructive pulmonary disease (COPD). Conclusion: Overall, lung cancer was found to be the leading cause of hemoptysis, with bronchiectasis being the leading cause in female patients and malignancy in male patients. Close monitoring of male patients is crucial due to higher mortality risk. Careful assessment of patients with hemoptysis having comorbidities such as diabetes and COPD is required due to the reduced survival rates associated with these conditions. Early detection and intervention for lung cancer is essential to optimize the prognosis of affected individuals.
- 15 August 2024
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 2 (3) , 52-57
Open AccessFrightening symptom hemoptysis: Analysis of etiology, mortality, and treatment outcomes in a large cohort from the chest disease center in Turkiye
Aims: Hemoptysis can indicate serious, potentially life-threatening conditions. The etiology varies by region and can include tuberculosis (TB) in developing countries and malignancies in developed regions. Methods: This retrospective cohort study reviewed medical records of 400 hospitalized hemoptysis patients between June 2012 and March 2016. Data collected included patient demographics, comorbidities, hemoptysis volume, diagnostic tests, treatments, and outcomes. Survival rates and readmissions were tracked for 2-6 years post-discharge. Results: Of the 400 patients, 88 (22%) were female and 312 (78%) were male. The leading causes of hemoptysis were bronchiectasis (14%), sequela of tuberculosis (TB sequelae; 19%), and malignancy (22.8%). The most common causes in male patients were lung cancer (27.2%) and TB sequelae (21.8%). Bronchiectasis accounted for 28.4% of cases in female patients, followed by drug-induced hemoptysis at 14.8%. The in-hospital mortality rate was 1% (n = 4), with severe hemoptysis present in all four patients who died during admission for hemoptysis. The 2–6-year survival rate was 70.8% for women and 56.1% for men (p = 0.005). The factors found to significantly worsen mortality risk were lung malignancy, age >65, diabetes, and chronic obstructive pulmonary disease (COPD). Conclusion: Overall, lung cancer was found to be the leading cause of hemoptysis, with bronchiectasis being the leading cause in female patients and malignancy in male patients. Close monitoring of male patients is crucial due to higher mortality risk. Careful assessment of patients with hemoptysis having comorbidities such as diabetes and COPD is required due to the reduced survival rates associated with these conditions. Early detection and intervention for lung cancer is essential to optimize the prognosis of affected individuals.
- 1 January 2024
- Published by Bayt Publications in The Turkish Journal of Geriatrics
- Vol. 27 (3) , 248-260
DO LATENT TUBERCULOSIS AND AGE IMPACT THE POST-COVID-19 EXPERIENCE?
Background: There is not enough information about the long-term effects of COVID-19 infection in those who have recovered. According to epidemiological studies, COVID-19 progresses less severely in countries where the Bacillus Calmette-Guerin vaccine is regularly applied than in those where it is not. The purified protein derivative of tuberculin is an indicator of the Bacillus Calmette-Guerin vaccine’s protective effectiveness against latent tuberculosis. In our study, we aimed to investigate the relationship between latent tuberculosisand the permanent effects of COVID-19.Our objective was to analyze the long-term relationship between latent tuberculosisand COVID-19. Materials and Method: We included all clinical, laboratory, and radiological baseline data of patients who were hospitalised for COVID-19 pneumonia between 2020 and 2021 during the pandemic in our study and compared them with data from six months later. Results: Although there was no statistically significant correlation between purified protein derivative of tuberculin positivity and the long-term effects of COVID-19 (p = 0.084), age exhibited a statistically significant relationship with the presence of post-COVID-19 sequelae (p = 0.004). Patients with chronic pulmonary disease displayed a significantly greater percentage of symptoms (p=0.005). Conclusion: We could not find any relationship between purified protein derivative of -tuberculin latent tuberculosis infection and long COVID-19 symptoms. We observed sequelae lesions more frequently in the follow-up of elderly patients. Post-COVID-19 symptoms were more common in patients with chronic lung disease. Thus, it is recommended to prioritise radiological and clinical follow-up in elderly patients and those with chronic lung conditions. Keywords: Post-Acute COVID-19 Syndrome, Latent Tuberculosis, COVID-19, Aged.
- 1 January 2024
- Published by Bayt Publications in The Turkish Journal of Geriatrics
- Vol. 27 (3) , 248-260
DO LATENT TUBERCULOSIS AND AGE IMPACT THE POST-COVID-19 EXPERIENCE?
Background: There is not enough information about the long-term effects of COVID-19 infection in those who have recovered. According to epidemiological studies, COVID-19 progresses less severely in countries where the Bacillus Calmette-Guerin vaccine is regularly applied than in those where it is not. The purified protein derivative of tuberculin is an indicator of the Bacillus Calmette-Guerin vaccine’s protective effectiveness against latent tuberculosis. In our study, we aimed to investigate the relationship between latent tuberculosisand the permanent effects of COVID-19.Our objective was to analyze the long-term relationship between latent tuberculosisand COVID-19. Materials and Method: We included all clinical, laboratory, and radiological baseline data of patients who were hospitalised for COVID-19 pneumonia between 2020 and 2021 during the pandemic in our study and compared them with data from six months later. Results: Although there was no statistically significant correlation between purified protein derivative of tuberculin positivity and the long-term effects of COVID-19 (p = 0.084), age exhibited a statistically significant relationship with the presence of post-COVID-19 sequelae (p = 0.004). Patients with chronic pulmonary disease displayed a significantly greater percentage of symptoms (p=0.005). Conclusion: We could not find any relationship between purified protein derivative of -tuberculin latent tuberculosis infection and long COVID-19 symptoms. We observed sequelae lesions more frequently in the follow-up of elderly patients. Post-COVID-19 symptoms were more common in patients with chronic lung disease. Thus, it is recommended to prioritise radiological and clinical follow-up in elderly patients and those with chronic lung conditions. Keywords: Post-Acute COVID-19 Syndrome, Latent Tuberculosis, COVID-19, Aged.
- Open Access
- 1 January 2022
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 23 (1) , 58-62
Co-infection of COVID-19 and Tuberculosis
Coronavirus,pandemic,rifampicin,SARS-CoV-2,treatment
- 1 January 2022
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 23 (1) , 58-62
Open AccessCo-infection of COVID-19 and Tuberculosis
Coronavirus,pandemic,rifampicin,SARS-CoV-2,treatment